Author

E. Charafe-Jauffret

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

C. Ginestier· 2 shared M. E. Peter· 2 shared P. Legembre· 2 shared A. Bessede· 1 shared A. Chaibi· 1 shared A. E. Murmann· 1 shared A. Mueller· 1 shared A. S. Qadir· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Ginestier

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

CD95 expression in triple negative breast cancer blocks induction of an inflammatory state through differential regulation of NF-kB Signaling

J.-P. Guegan, J. Pollet, C. Ginestier, E. Charafe-Jauffret, M. E. Peter, P. Legembre

This study identifies CD95 interaction partners KPC2 and p65, showing CD95 loss in TNBCs promotes NF-κB activation and pro-inflammatory cytokine production.

bioRxiv · Apr 7, 2021 · PreprintCancer Biology

Tumor expressed CD95 causes suppression of anti-tumor activity of NK cells in a model of triple negative breast cancer

A. S. Qadir, J. P. Guegan, C. Ginestier, A. Chaibi, A. Bessede, E. Charafe-Jauffret, M. Macario, V. Lavoue, T. de la Motte Rouge, C. Law, J. Vilker, H. Wang, E. Stroup, M. J. Schipma, B. Bridgeman, , M. E. Peter

This study shows that CD95 expression by tumor cells suppresses NK cell anti-tumor activity in triple negative breast cancer, leading to reduced tumor growth in immune-competent mice.

bioRxiv · Feb 12, 2021Cancer Biology

Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance

F. Lamballe, F. Ahmad, Y. Vinik, O. Castellanet, F. Daian, A. Mueller, U. Koehler, A.-L. Bailly, E. Josselin, R. Castellano, C. Cayrou, E. Charafe-Jauffret, G. B. Mills, V. Geli, J.-P. Borg, , F. Maina

This study develops a mouse model of TNBC that recapitulates human tumor heterogeneity and identifies a synergistic combination of WEE1 and BCL-XL inhibition as a potential treatment.

bioRxiv · Jun 22, 2020Cancer Biology